Evaluation of 8‐week glecaprevir/pibrentasvir treatment in direct‐acting antiviral‐naïve noncirrhotic HCV genotype 1 and 2infected patients in a real‐world setting in Japan-Reference-Cited by-同舟云学术

Evaluation of 8‐week glecaprevir/pibrentasvir treatment in direct‐acting antiviral‐naïve noncirrhotic HCV genotype 1 and 2infected patients in a real‐world setting in Japan

Published:2019-08-09 Issue:11 Volume:26 Page:1266-1275
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Ikeda Hiroki¹^ORCID,Watanabe Tsunamasa¹,Atsukawa Masanori²^ORCID,Toyoda Hidenori³^ORCID,Takaguchi Koichi⁴,Nakamuta Makoto⁵,Matsumoto Nobuyuki¹,Okuse Chiaki¹,Tada Toshifumi³,Tsutsui Akemi⁴,Yamashita Naoki⁵,Kondo Chisa²,Hayama Korenobu²,Kato Keizo⁶,Itokawa Norio⁷,Arai Taeang²,Shimada Noritomo⁸,Asano Toru⁹,Uojima Haruki¹⁰,Ogawa Chikara¹¹,Mikami Shigeru¹²,Ikegami Tadashi¹³,Fukunishi Shinya¹⁴,Asai Akira¹⁴,Iio Etsuko¹⁵,Tsubota Akihito¹⁶,Hiraoka Atsushi¹⁷,Nozaki Akito¹⁸,Okubo Hironao¹⁹,Tachi Yoshihiko²⁰,Moriya Akio²¹,Oikawa Tsunekazu²²,Matsumoto Yoshihiro²³,Tsuruoka Shuichi²⁴,Tani Joji²⁵,Kikuchi Kan²⁶,Iwakiri Katsuhiko²,Tanaka Yasuhito¹⁵,Kumada Takashi³

Affiliation:

1. Department of Internal Medicine St. Marianna University School of Medicine Kawasaki Japan

2. Department of Internal Medicine, Division of Gastroenterology and Hepatology Nippon Medical School Tokyo Japan

3. Department of Gastroenterology Ogaki Municipal Hospital Ogaki Japan

4. Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan

5. National Hospital Organization Kyushu Medical Center Fukuoka Japan

6. Department of Internal Medicine, Division of Gastroenterology and Hepatology Shinmatusdo Central General Hospital Matsudo Japan

7. Department of Internal Medicine, Division of Gastroenterology Nippon Medical School Chiba Hokusoh Hospital Inzai Japan

8. Department of Internal Medicine, Division of Gastroenterology and Hepatology Otakanomori Hospital Kashiwa Japan

9. Department of Internal Medicine, Division of Gastroenterology and Hepatology Tokyo Metropolitan Bokutoh Hospital Tokyo Japan

10. Department of Gastroenterology, Internal Medicine Kitasato University School of Medicine Kanagawa Japan

11. Department of Gastroenterology and Hepatology Takamatsu Red Cross Hospital Takamatsu Japan

12. Department of Internal Medicine, Division of Gastroenterology Kikkoman General Hospital Noda Japan

13. Ibaraki Medical Center Tokyo Medical University Ibaraki Japan

14. Second Department of Internal Medicine Osaka Medical College Osaka Japan

15. Department of Virology & Liver Unit, Graduate School of Medical Sciences Nagoya City University Aichi Japan

16. Core Research Facilities for Basic Science The Jikei University School of Medicine Tokyo Japan

17. Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan

18. Gastroenterological Center Yokohama City University Medical Center Kanagawa Japan

19. Department of Gastroenterology Juntendo Nerima University Hospital Tokyo Japan

20. Bantane Hospital Fujita Health University School of Medicine Nagoya Japan

21. Department of Gastroenterology Mitoyo General Hospital Kannonji Japan

22. Department of Gastroenterology and Hepatology The Jikei University School of Medicine Tokyo Japan

23. Department of Gastroenterology and Hepatology The Jikei University School of Medicine, Kashiwa Hospital Kashiwa Japan

24. Department of Internal Medicine, Division of Nephrology Nippon Medical School Tokyo Japan

25. Department of Internal Medicine Yashima General Hospital Takamatsu Japan

26. Shimo‐Ochiai Clinic Tokyo Japan

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13170

Reference31 articles.

1. In vitro antiviral activity and resistance profile of the next‐generation hepatitis C virus NS3/4A Protease Inhibitor Glecaprevir;Ng TI;Antimicrob Agents Chemother,2018

2. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir

3. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

4. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

5. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of glecaprevir/pibrentasvir in patients with chronic hepatitis C or compensated cirrhosis in daily clinical practice: a drug-use results survey;Kanzo;2022-03-01

2. Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed;Internal Medicine;2021-11-01

3. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection;Annals of Palliative Medicine;2021-10

4. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C;PLOS ONE;2021-09-10

5. Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group;Journal of Medical Virology;2021-07-03